Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 22, 2009
Wed, January 21, 2009 Iris BioTechnologies Launches Health Passport in Its BioWindows" 2.0 Informatics System for Personalized and Targeted Medicine
SANTA CLARA, Calif.--([ BUSINESS WIRE ])--Iris BioTechnologies (OTCBB:IRSB) ([ http://www.irisbiotech.com ]), a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, has launched its proprietary BioWindows™ 2.0 to further the progress of personalized and targeted medicine.
In his inaugural speech President Obama stated, "We will restore science to its rightful place and wield technology's wonders to raise health care's quality and lower its cost." As a junior senator from Illinois Mr. Obama introduced S.B. 3822, "The Genomics and Personalized Medicine Act." The Act's goal is to "improve access to and appropriate utilization of valid, reliable, and accurate molecular genetic tests by all populations, thus helping to secure the promise of personalized medicine for all Americans."
The new administration's vision is clear but without the proper technologies the road is blocked. For the past ten years Simon Chin, Founder and CEO of Iris BioTechnologies, and his team have been developing the necessary tools to make the President's vision of personalized medicine for all Americans a reality. These include the Iris BioWindows™ informatics system and Nano-Biochip™ gene-profiling platform, a powerful combination that enables the practice of personalized medicine through the analysis of gene profiles and comprehensive life dynamics.
BioWindows™ is a HIPAA compliant, web based, medical information storage system that allows participants to grant selective or full sharing capabilities of their confidential medical and lifestyle information to physicians or family members anywhere in the world. This allows families to build multi-generational medical family trees that will help assure that they receive more personalized care now and in the future – the right medical treatment for the right patient at the right time. Many users of the system consider it their essential "Medical Passport" as they and their children and grandchildren participate in our increasingly global society.
The other essential tool for personalized medicine is the ability to measure the behavior of the many genes that are malfunctioning in any particular disease. The major diseases that inflict so much pain and suffering on our population are not caused by the inheritance of faulty genes but by genes malfunctioning over time due to lifestyle and other easily measured factors. The Iris Nano-Biochip™ platform is designed to clinically measure each patient's unique genomic profile.
Combining these two tools, BioWindows™ and the Nano-Biochip™, will offer physicians a unique perspective concerning the relationship of a patient's genes and their lifestyle dynamics, according to Mr. Chin. Armed with this information clinicians can truly personalize their medical treatments raising the quality of our health care system and lowering its cost.
In 2008, The Dr. Susan Love Research Foundation and Avon joined forces to recruit an Army of Women to help eradicate breast cancer. Iris BioTechnologies has dedicated the past decade to developing the necessary tools and technologies to answer that challenge. Disease eradication will only come from a mobilized grass roots effort by millions of concerned citizens with access to the proper tools. Won't it be nice when we can answer our 44th President's "yes we can" challenge with "yes we did" eradicate breast cancer.
Last month, Iris BioTechnologies was selected, through a competitive screening process, by the Biotechnology Industry Organization (BIO) to present at the Eleventh Annual BIO CEO & Investor Conference in New York on February 9-10, 2009. "We are looking forward to presenting BioWindows™ 2.0 and our Nano-Biochip technology platform at this major investor conference," said Mr. Chin, CEO of Iris BioTechnologies.
Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO, said, "These leading companies represent the industry's most promising investment opportunities with late‐stage clinical pipelines, well‐established business strategies or strong M&A potential. Selected companies are also distinguished by significant opportunities for value creation with near‐term clinical, regulatory and corporate catalysts that will help to support our industry through the current economic downturn."
When Frost and Sullivan bestowed Iris with their prestigious 2008 Technology Innovation Award in Pharmacogenomics, they said, "Iris's technology is a near-term opportunity, which would significantly transform the way in which personalized medication is currently being prescribed."
"It is very reassuring that both the Biotechnology Industry Organization (BIO) and Frost and Sullivan, using their own independent criteria and research, see the same potential for Iris to grow and make a positive impact in the near future," said Mr. Chin.
For more information, please visit the corporate website: [ www.irisbiotech.com ]
About Iris BioTechnologies
Iris BioTechnologies ([ www.irisbiotech.com ]), located in Santa Clara, CA, is a life sciences company, dedicated to creating a novel approach to monitor gene expression levels and mutations in order to identify the ideal treatment solution for patients. By categorizing individuals according to their genomic and personal profiles, Iris BioTechnologies accurately determines the optimal medical solution for each patient through a proprietary informatics system, BioWindows. Iris's ever expanding database, in addition to their development of the Breast Cancer Chip™, Comprehensive Cancer Chip™, NeuroChip™, CardioChip™, and MetabolicChip™ adds to their extensive product pipeline.
Forward-Looking Statements
The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
